Agile Therapeutics (AGRX) Peer Comparison

$1.51

$0.00 (0.00%)

As on 26-Aug-2024 15:20EDT

Market cap

$10 Mln

Revenue (TTM)

$22 Mln

P/E Ratio

--

P/B Ratio

1.8

Div. Yield

0 %

Edit

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Market cap ($ Mln)	10	35
Revenue ($ Mln)	22	0
Net Profit ($ Mln)	-15.86	-7.20
Net Margin (%)	-73.52	-4,090.91
RoE (%)	--	-20.69
Price to Earnings	--	--
Price-To-Book	1.79	1.07

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Operating Revenue	21.57	0.18
Cost of Revenue	7.84	0.08
Gross Profit	10.62	-0.11
Operating Expenses	27.28	8.73
Operating Profit (EBIT)	-13.56	-8.76
Other Income	0.00	0.00
Profit before Tax	-15.86	-7.20
Provision for Tax	0.39	0.95
Profit after Tax (Net Income)	-15.86	-7.20
Minority Interest	0.00	0.00
Consolidated Profit	-0.80	-1.42

Liabilities ($ Mln)

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Shareholder's Funds	-21.91	32.57
Minority Interest	0.00	0.00
Non-Current Liabilities	10.65	0.00
Current Liabilities	26.23	1.27
Total Liabilities	10.26	37.86

Assets ($ Mln)

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Non-Current Assets	0.52	0.02
Current Assets	14.44	33.82
Total Assets	10.26	37.86
Total Debt*	0.29	0.02
Net Current Assets	-11.79	32.55

Cashflow ($ Mln)

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Cash From Operating Activities	-9.58	-5.01
Cash Flow from Investing Activities	--	--
Cash from Financing Activities	6.89	--
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
ROCE (%)	165.50	-13.47
ROE (%)	132.32	-20.69
ROA (%)	-45.92	-18.51
EBIT Margin (%)	-33.51	-4,994.89
Net Margin (%)	-73.52	-4,090.91
Cash Profit Margin (%)	0.00	-0.05

Growth Ratios

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Revenue Growth (%)	32.21	--
EBIT Growth (%)	72.24	-11.31
Net Profit Growth (%)	62.90	-51.01
EPS Growth (%)	93.78	--
Book Value Growth (%)	53.34	--

Valuation Ratios

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Price / Earnings	-0.40	--
Price / Book Value	-0.35	--
Dividend Yield (%)	--	--
EV/EBITDA	-0.27	5.09
Market Cap ($ Cr)	--	--

Solvency Ratios

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	-0.01	0.00
Current Ratio	0.55	26.61
Quick Ratio	0.33	26.61
Interest Coverage	-18.08	-15.00

Operating Efficiency Ratios

	Agile Therapeutics (AGRX)	ARCA Biopharma Inc (ABIO)
Debtors to sales (%)	21.10	0.00
Asset Turnover	0.62	0.00
Receivable days	63.09	--
Inventory Days	82.79	--
Payable days	352.07	1,145.11
Cash Conversion Cycle	-206.19	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly